ZNTL (Zentalis Pharmaceuticals) Property, Plant and Equipment: $28.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZNTL Zentalis Pharmaceuticals Inc ZNTL
32 GF Score
Price $5.09
! 3 Warning Signs
View Full Analysis

What is Zentalis Pharmaceuticals Property, Plant and Equipment?

Zentalis Pharmaceuticals ZNTL +12.06% 32 Property, Plant and Equipment is $28.25 Mil as of Mar. 2026. GuruFocus rates ZNTL with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Zentalis Pharmaceuticals's quarterly net PPE declined from Sep. 2025 ($33.12 Mil) to Dec. 2025 ($29.04 Mil) and declined from Dec. 2025 ($29.04 Mil) to Mar. 2026 ($28.25 Mil).

Zentalis Pharmaceuticals's annual net PPE declined from Dec. 2023 ($41.74 Mil) to Dec. 2024 ($37.23 Mil) and declined from Dec. 2024 ($37.23 Mil) to Dec. 2025 ($29.04 Mil).


Zentalis Pharmaceuticals  (NAS:ZNTL) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Zentalis Pharmaceuticals Property, Plant and Equipment Related Terms


Zentalis Pharmaceuticals Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Zentalis Pharmaceuticals's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zentalis Pharmaceuticals Property, Plant and Equipment Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Property, Plant and Equipment
Get a 7-Day Free Trial 52.84 50.08 41.74 37.23 29.04

Zentalis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.17 34.26 33.12 29.04 28.25
ZNTL
32GF Score
Zentalis Pharmaceuticals Inc ZNTL
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zentalis Pharmaceuticals Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of $28.25 Mil mean?
Zentalis Pharmaceuticals (ZNTL) has a Property, Plant and Equipment of $28.25 Mil as of Mar. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Zentalis Pharmaceuticals and its competitors.
Is Zentalis Pharmaceuticals' Property, Plant and Equipment too high?
Zentalis Pharmaceuticals' current Property, Plant and Equipment is $28.25 Mil. Overall, Zentalis Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Zentalis Pharmaceuticals' Property, Plant and Equipment compare to ELDN and GLSI?
Zentalis Pharmaceuticals' Property, Plant and Equipment of $28.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Biotechnology company?
A good Property, Plant and Equipment depends on the Biotechnology industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Zentalis Pharmaceuticals and its competitors. Zentalis Pharmaceuticals's current Property, Plant and Equipment is $28.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentalis Pharmaceuticals stock overvalued right now?
Zentalis Pharmaceuticals (ZNTL) has a current Property, Plant and Equipment of $28.25 Mil. The current Property, Plant and Equipment is $28.25 Mil. Zentalis Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Zentalis Pharmaceuticals (ZNTL), the current Property, Plant and Equipment is $28.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zentalis Pharmaceuticals Business Description

Address 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
32GF Score

Get the complete analysis for ZNTL

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price